Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Intellipharmaceutics International Inc V.IPCI.H

Alternate Symbol(s):  IPCIQ

Intellipharmaceutics International Inc. is a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that can be applied to a range of existing and new pharmaceuticals. It has developed several drug delivery systems based on this technology platform, with a pipeline of products in various stages of development. The Company has ANDA and NDA 505(b)(2) drug product candidates in its development pipeline. These include the Company’s abuse-deterrent oxycodone hydrochloride extended-release formulation (Oxycodone ER) based on its proprietary nPODDDS novel Point of Divergence Drug Delivery System (for which an NDA has been filed with the FDA), and Regabatin XR (pregabalin extended-release capsules). Its product portfolio includes both new products and controlled-release generic products.


TSXV:IPCI.H - Post by User

Post by Nogah3on Jan 16, 2020 1:36am
233 Views
Post# 30558905

Pipeline

Pipeline

Hi all,

Lots of chatter about what typically goes on with companies like this. To provide some clarity, I think we need to look at the real reason that drove the company's resurgence over the last month.

IPCI already has 6 FDA approved drugs (with one other pending approval). The US Market size for these is $2.44 Billion. Recently, Exclusive Licence and Commercial Supply agreements were signed with Tris Pharma for Quetiapine (Aug 15), Desvenlafaxine (Sep 5), and Velafaxine (Nov 25). These signings reach the same market size as Oxycodone ($1.3 Bil). So the stock price explosion from $0.20 to $1.20 is appropriate. Why? Because revenue is about to get a boost in Q4, even without Oxycodone.

And let's not forget a few things:
(1) the company also has the FDA approved Dexmethylphenidate (ADHD drug) already producing revenue
(2) there are two other FDA approved drugs (Metformin for diabetes and Levetiracetam for seizures) yet to be licenced out for additional revenue
(3) there are five other drugs in the works (excluding Oxycodone) that together have a market size of $7.63 Bil.
(4) Oxycodone ER can still be approved by FDA at a later date once the company provides evidence that it is unlikely to be abused by snorting

Given the recent signings and great potential, I am not surprised that this company's projected 1 year price target exceeds $10. 

Anyhow, I hope this sheds light on things, and helps you make an informed decision.
source: https://www.intellipharmaceutics.com/product-pipeline
-----------------------------------------------------------------------------------------

<< Previous
Bullboard Posts
Next >>